Tag Archive for: NICE

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)

/in

London, UK, Barcelona, Spain and Düsseldorf, Germany – 5 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for Health and Care Excellence (NICE) in the UK has issued a positive recommendation for the use of ublituximab (150 mg concentrate […]

Read more

This week’s hot topic: Why Pharma will have to play the long game on Alzheimer’s drugs

/in

By Stephen Adams, Optimum Strategic Communications Few people expected England and Wales’s drugs spending watchdog, the National Institute for Health and Care Excellence (“NICE”), to approve Eli Lilly’s new dementia drug donanemab for use on the NHS last week.  At a reputed annual cost of at least £60,000 a year, including the care bill, it […]

Read more